Wockhardt completes Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873
Wockhardt has announced the completion of the pivotal Phase 3 pneumonia Study of its macrolide antibiotic Nafithromycin WCK 4873.
Wockhardt completes Phase 3 pneumonia study of its macrolide antibiotic Nafithromycin WCK 4873 Read More